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Steroid withdrawal in clinical trials
In chapter 3, we described that withdrawal of inhaled corticosteroids (ICS) in
patients with stable COPD results in an increase in inflammation and airway
obstruction. We furthermore explored the inflammatory mechanisms possibly
responsible for these effects. These detrimental effects occurred even when the
patients seemed clinically stable since patients experiencing an exacerbation
were treated accordingly and left out of this analysis. These effects of steroid
withdrawal have been described in several studies (1;2), but there is little insight
on what causes this deterioration. We found that particularly sputum eosinophils
increased after steroid withdrawal, which was accompanied by worsening of
airway obstruction and quality of life. 
Many studies have a run-in phase, in which ICS are withdrawn to avoid the bias
that the baseline airway inflammation is variably modified by different ICS usage.
New trials should reconsider this approach, for several reasons. Firstly,
withdrawal by itself also induces bias: withdrawal of ICS induces differences in
baseline inflammation, as not all patients respond the same to ICS withdrawal.
Secondly, many patients exacerbate soon after withdrawal. Frequently, these
patients are then excluded from the trial, resulting in a selection bias of patients
towards a group with less tendency to deteriorate after ICS withdrawal. A third
consideration is the dilemma whether it is ethical stop ICS with a subsequent
increased risk of exacerbations for the sake of a study. These patients become
more symptomatic, and may need additional (systemic) steroid treatment with
associated potential side effects. For real life (not experimentally induced)
exacerbations it has been demonstrated that patients sometimes do not fully
recover form exacerbations to pre-exacerbation levels particularly for peak
expiratory flow values (3).
ICS withdrawal is applied to obtain equal baseline values in COPD patients, and
as mentioned above, this is a pitfall. Should we then investigate other ways that
avoid steroid withdrawal? Reduction of steroid treatment in all patients to a
similar low dose maintenance treatment may be a solution to this problem. But
again a similar dose of ICS may have different effects in an individual patient
with COPD. Another option is a gradual withdrawal of steroids, which might
results in less deterioration of inflammation and respiratory symptoms. Other
ways around this problem would be stratification for baseline steroid use, or
even an increase in steroid use to a high dose for all study participants. Future
studies should investigate if these options improve the methodology of trials and
reduces symptoms for patients.
Non-invasive measurement of inflammation during COPD exacerbations
In chapter 4 we showed that it is safe and feasible to study the cellular patterns
of airway inflammation by sputum induction using a hypertonic saline solution
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even during acute exacerbations of COPD. We assessed the safety in mild to
moderate exacerbations that did not require hospitalisation. Sputum inductions
have been assessed in several settings, but there is little data on safety (4-6).
These studies did not all use the same induction protocol (i.e. duration,
concentration and number of nebulised saline inhalations), which makes it
difficult to compare both the safety and the results of the various studies on
airway inflammation during COPD exacerbations. It would be worthwhile to study
the various protocols systematically, in order to reach consensus on a universal
protocol for sputum induction during COPD exacerbations with the best
properties with respect to safety and a reproducible reflection of the cellular
airway inflammation.  
Not only inflammatory cells, but also non-cellular biomarkers provide information
on airway inflammation. Thus far, cytokines have given us insight in the
mechanisms that play a role in COPD in a stable phase and during
exacerbation. However, the measurement of cytokines in sputum of COPD
patients plays little to no role in current clinical practice.
 We foresee a potential future role for measurement of cytokines during COPD
exacerbations in the decision to prescribe antibiotics: in chapter 5, we have
shown that sputum biomarkers might be useful to distinguish a bacterial from a
non-bacterial origin of exacerbation. C-reactive protein (CRP) and procalcitonin
are the most elaboratively investigated markers for this purpose. CRP has been
evaluated as a marker to define an exacerbation, but was only useful in
combination with a major exacerbation symptom. Procalcitonin-guided therapy
has been shown to reduce antibiotics prescription, however the marker does not
have ideal predictive characteristics of bacterial infections in COPD
exacerbations, since both its specificity and sensitivity appear to be poor (7-9).
From our data, sputum tumor necrosis factor-a seemed to be a potential marker
to identify a bacterial cause of exacerbation. However, our study population was
not large enough to provide firm data on its usefulness or on the best cut-off
point. Nevertheless, if the favourable predictive value for a bacterial infection of
sputum tumor necrosis factor-a levels could be confirmed in a large study, this
might lead to a novel objective guide for administering antibiotics in COPD
exacerbations, perhaps in conjunction with other parameters such as
procalcitonin.
In chapter 5, we studied the relationship between the cause of an exacerbation
and the inflammatory pattern. In 7 out of 28 exacerbations we identified a
bacterial infection as the cause. Viral and bacterial infections and air pollution
are well known causes of exacerbations (10;11). Nevertheless, in up to 30 % of
exacerbations, the cause remains unknown (12). Perhaps these causes remain
unknown due to limitations in our ability to detect viruses, or due to our lack of
understanding of other causes. Identification of these causes would lead to a
better understanding of the inflammation associated with of COPD
exacerbations, and explain why some patients do not respond to conventional
steroid therapy. It might also open windows to new pathways of treatment.
Gastro oesophageal reflux (GER) might be such an unidentified cause. GER is
well known to cause respiratory symptoms. In asthma, GER is a cause of
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increased respiratory symptoms, which responds well to anti-reflux treatment
(13). These increased symptoms are thought to be attributable to aspiration of
gastric acid, causing a neutrophilic inflammation in the airways (14). There is
little research on the role of GER in COPD. Nevertheless, a few studies have
shown that GER is more prevalent in COPD patients than in controls and
furthermore a trend has been observed towards more severe COPD in
individuals in whom GER exists (15-17). An increased prevalence of GER in
COPD patients has been shown by reflux questionnaires and by oesophageal
pH measurement (15;18).
At present, it is not known if an episode of increased GER can cause an
exacerbation in COPD patients. However, patients with GER do have a much
higher exacerbation rate compared to patients without GER, suggesting a
causative role for GER in COPD exacerbations (19). In vitro research shows that
exposure of bronchial epithelial cells with reflux, and particularly the stomach
fluid component pepsin, an enzyme involved in protein break-down, induces
release of interleukin -6 and interleukin-8, pro-inflammatory cytokines reported
to be increased during COPD-exacerbations (figure 1). In summary, it seems
important to ask patients with COPD about GER symptoms in clinical practice.
Treatment of COPD exacerbations with inhaled budesonide and formoterol.
In chapter 6, we analysed the effectiveness of budesonide/formoterol (B/F) in
the treatment of COPD exacerbations. The treatment with B/F compared to oral
prednisolone seemed to have similar effects on airway eosinophils and
symptoms, and even better effects on both airflow limitation and health status.
These encouraging results are to be confirmed in future large trials.
Furthermore, we studied the outpatient treatment of mild to moderate COPD
exacerbations. Whether the effects are the same in hospitalised patients with
more severe exacerbations is an interesting and important research and clinical
question to be studied in future trials. To answer, at least in part, these questions
raised from the Symbexco trial, a large multicenter trial has already started
(ClinicalTrials.gov Identifier: NCT00259779). We look forward to the results of
these trials, since they might confirm our results of positive effects with B/F
instead of prednisolone in the treatment of COPD exacerbations.
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Figure 1: Induction of IL-8 release by pepsin: effect of pepsin dose and pH.
Interleukin-8 was corrected for cell proliferation and expressed as a % of exposure with the
corresponding pH without pepsin (control). There is a difference in interleukin-8 release induced by
pepsin between the pH levels (F=5.1; p<0.01). Interleukin-8 release induced by pepsin is higher at
pH 1.5 compared to pH 2.5 (mean difference 221%; p<0.01). Data expressed as mean (histograms)
and SEM (bars) for 3 replicates.
It would be an interesting option to treat exacerbations at home at the onset of
an evolving exacerbation by B/F. We hypothesize that treatment with an
increased dose B/F, which the patients already might use as maintenance
therapy, would reduce the delay of steroid treatment which frequently occurs
with oral steroids. The early onset of steroid treatment, which is facilitated by this
treatment strategy, might reduce the exacerbation severity, or even prevent an
full-blown exacerbation In asthma, this treatment strategy improves the time to
the first exacerbation, respiratory symptoms, and lung function, and reduced the
rate of severe exacerbations (20). Figure 2 shows a suggestion for a simple
double-blind randomised controlled trial design to assess whether the early
increase of B/F treatment could prevent the development of full-blown
exacerbations leading to hospitalisations. In this trial patients would be included
in a stable phase, and all patients would receive B/F maintenance treatment in
their stable phase. Patients would be randomised to use increased dose B/F or
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placebo for two weeks at the onset of increasing symptoms, with additional short
acting bronchodilators as needed in both groups. The patients should be
instructed to contact the physician when a full blown exacerbation develops,
requiring open label prednisolone treatment. The rescue use of prednisolone
would be the (primary) endpoint of the study. If health improves, the patients
continue their maintenance treatment after the 2 weeks of add-on trial treatment.
During each subsequent period of increased symptoms the trial medication
would again be used, until there is a need for open label prednisolone treatment,
or 1000 days have passed, whichever comes first. During baseline and the trial
treatment periods, symptoms and quality of life should be recorded, and at the
end of baseline and treatment periods lung function, adverse symptoms related
to steroid treatment, and responsiveness to methacholine would be measured.
These would be analysed as secondary endpoints (need for open label
prednisolone is the primary endpoint, as mentioned above).
Figure 2: Study design to investigate effectiveness of increasing B/F maintenance dose in the
prevention of full blown COPD exacerbation*All patients receive maintenance therapy B/F in a
dose of 200µg /6µg, twice daily, and shorting acting bronchodilators as needed. ‡ All patients
continue to use the maintenance therapy. The patients randomised for B/F treatment use the
inhaler containing the additional B/F in a dose of 200µg/6µg four times daily; the patients
randomised for placebo use the placebo-inhaler four times daily.
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Inflammatory cells to measure treatment outcome.
In the SYMBEXCO-study, described in chapter 6, we used sputum eosinophils
as the primary endpoint to measure the outcome of treatment effect by steroids.
We hypothesized that this inflammatory cell would be a valid endpoint for
several reasons.
The first reason for choosing eosinophils as primary endpoint, is that various
studies have found eosinophils to be increased during COPD exacerbations, as
summarised in  table 2 of the review of chapter 2 (4;5;21;22). We confirmed this
increase (chapter 5). Although all these studies and we found an increase in
airway eosinophil counts during exacerbations, this does not necessarily mean
that eosinophils are actively involved in the increase in respiratory symptoms
during COPD exacerbations. Causality has not been found so far, but our study
provided some contributing evidence for this: we found a correlation between the
increase in eosinophils form stable phase to exacerbation and a decrease in
FEV1, although the relationship was weak. However, we did not find a
relationship between improvements in FEV1 and health status and decrease in
sputum eosinophils during the trial treatment. This does not necessarily rule out
a role for eosinophils during COPD exacerbations: The lack of association
between change in sputum eosinophils and other treatment effects as airway
obstruction and health status might be explained by the limited number of
patients in our study, and a third of these patients did not receive steroid
treatment, but placebo. Therefore we might not have had the power to show
such a relationship. A second explanation might be that eosinophils are not
involved in all COPD exacerbations, but in a subgroup. Papi et al showed that
eosinophils were only increased in exacerbations with a viral infection(4), and




Figure 3: Increase in sputum eosinophils from a stable phase on varying types and dosages of
inhaled steroids (visit 1), via steroid withdrawal for 2 months, to the beginning of a COPD
exacerbation. Sputum eosinophil numbers are significantly increased during the exacerbation
compared to the numbers at the inclusion visit. However, there is a large group of patients with
COPD, in which sputum eosinophils are at a low numbers during an exacerbation, indicating that
eosinophils increase only in a subgroup of patients.
The second reason to choose eosinophils as primary endpoint is based on
reports showing that sputum eosinophils are responsive cells to steroids.
Several studies reported that patients with COPD in a stable phase and high
eosinophil levels in sputum had better outcomes in FEV1 and symptoms when
treated with steroids, either orally or inhaled (23-25). In COPD exacerbations,
outcomes of steroid treatment depending on sputum eosinophil levels have not
been tested. An interesting question would be whether patients with low
eosinophil numbers in sputum benefit from steroid treatment at all, in stable
phase or exacerbation. To study this, the large COPD exacerbation trials
investigating the effects of steroid treatment, on which the evidence of steroid
treatment during exacerbations is based, should be repeated,this time with
measurement of the inflammatory characteristics of patients.
We could also have chosen airway neutrophil counts to assess
anti-inflammatory effects of B/F during COPD exacerbations: airway neutrophil
counts are increased during COPD exacerbations, as summarised in table 1 of
the review (chapter 2). In chapter 5 we confirmed that neutrophil numbers are
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increased during COPD exacerbations. Additionally, neutrophilic inflammation
has been related to airflow limitation and severity of symptoms (4;26). Therefore,
inhibition of neutrophil recruitment might be a strategy to treat COPD
exacerbations. Leukotrienes are important neutrophil-recruiting cytokines during
COPD exacerbations (27-29). Therefore inhibition of leukotriene activity could
cause a reduction in neutrophils. Indeed, the treatment of patients with stable
COPD with a leukotriene receptor antagonist resulted in reduction in neutrophils,
and improvement in symptoms, quality of life and airway obstruction (30). Since
we and others found that neutrophils are especially increased in exacerbations
caused by bacterial infections, and neutrophils are known to be involved in the
eradication of bacteria (27;31), the investigation of treatment of COPD
exacerbation with “anti-neutrophil” therapy should be instituted under strict
supervision and we would recommend anti-bacterial protection during such
trials, to reduce the chance of bacterial overgrowth and pneumonia.
Future anti-inflammatory therapies in COPD exacerbations: inhalation of carbon
monoxide?
In this thesis, we described two intervention trials with inflammation modifying
drugs: budesonide/formoterol and inhaled carbon monoxide. We presumed that
reduction of inflammation is beneficial and decreases symptoms. This was
based on reports of trials in a stable phase, which showed that steroid therapy is
beneficial in patients with a higher sputum eosinophil level (23;25), and that the
reduction of eosinophils is the pathway by which steroids reduce airway
obstruction in COPD (24). The effects of budesonide/formoterol were very
encouraging, and when the indications of the treatment effects of our pilot study
can be confirmed in a larger trial, this would shape the future of home treatment
of COPD exacerbations. 
The use of inhaled carbon monoxide is not so close to clinical treatment of
COPD exacerbation yet: we started to explore the effects of carbon monoxide in
stable COPD population (chapter 7), which –as far as we are aware- was the
first trial in humans to study the beneficial effects of carbon monoxide in COPD.
We did not find significant effects on sputum neutrophil counts, the primary
outcome parameter; although the median sputum neutrophil count was much
lower (median 2.6 compared to 4.0 x106/ml) after CO treatment compared to
placebo, the variability in our small study population was too large, resulting in
insignificant p-values. We did find a trend of reduction in eosinophils by
CO-inhalation. In vivo studies have shown that this anti-inflammatory effect of
carbon monoxide is caused by inhibition of the mitogen activated protein
(MAP)-kinase pathway. MAP-kinase pathways are a group of pathways which
have in common that they are involved in the signal transduction from an
external inflammatory stimulus to an inflammatory response of the cell, by
activating intracellular transcription factors of pro-inflammatory cytokines (32).
To explore which anti-inflammatory mechanisms are affected by CO inhalation
in humans, we performed additional measurements of the cytokines
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8-isoprostane (figure 4), IL-1ß, IL-5 IL-6, IL-8, IL-10, vascular epithelial growth
factor, and tumor necrosis factor-a. We were unable to confirm the effects on
cytokines by CO found in in vitro and in vivo studies: none of these cytokine
levels were significantly reduced by CO inhalation. Possible explanations for this
lack of effects on these cytokines could be that the dose of CO was too low, or
that our “inflammatory model”, the ongoing inflammation in COPD patients who
were not current smokers, provided insufficient levels of the inflammatory
cytokines to measure effects of CO.
Figure 4. Effects of carbon monoxide on the levels of 8-Isoprostane (urine).
Future studies on the therapeutic application of inhaled CO should investigate its
effects in a larger population of patients, assessing the safety and optimal
dosing schemes. Only when such studies show positive results, more severe
indications as COPD exacerbations could be investigated with sufficient
confidence.
Improvements in treatment of COPD exacerbations in the near future.
In the upcoming years, treatment of COPD exacerbations should be improved
by various approaches. Both basic scientific research and clinical research is
needed to achieve this.
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Firstly, novel anti-inflammatory drugs should be developed for the treatment of
COPD exacerbations. There is a need for novel drugs, since the effects of
steroids in the treatment of exacerbations are modest.  To make this possible,
there is a need for models to test these. So far, there are no animal models
resembling COPD exacerbations. The development of validated COPD
exacerbation models in animals would be a step forward in the search for more
efficient treatments of COPD exacerbations.
Secondly, as long as we do not have more efficient therapies in the treatment of
COPD exacerbations, we need to improve the current treatment. An important
step in this is the assessment of the optimal dose, and duration of steroid
treatment. There is hardly any data on the optimal dose and duration of systemic
steroid treatment in COPD exacerbations. Only one trial has assessed the
difference between 2 week and 8 week steroid treatment (33). Shorter steroid
schedules have to the best of our knowledge not been compared. Given the
large number of COPD patients treated with steroids every year, this urgently
calls for future investigations to provide evidence. There is also a marked
paucity of data regarding the dose of systemic steroids. Clinical guidelines
recommend prednisone 40 mg orally once/day for 10 days in patients with an
acute exacerbation of COPD (34). This was based on a panel consensus
judgment.
Thirdly, we need a better understanding of the course of COPD exacerbations.
Future studies should further investigate the relation between cause of
exacerbation, inflammatory mechanisms and susceptibility to treatment drugs.
Previous studies have shown that the various causes of COPD exacerbations
are associated with different inflammatory patterns. It is likely that the various
causes of exacerbation also require specific treatment. For instance, future
investigations need to assess whether exacerbations caused by bacteria with a
neutrophilic inflammation pattern respond to steroid treatment at all. Perhaps
these types of exacerbations should be treated with antibiotics and
bronchodilators only. On the other hand, viral exacerbations with may induce
with eosinophilia might respond reasonably well to steroid treatment, and might
not benefit from treatment with antibiotics. Exacerbations caused by
micro-aspiration might only respond to anti-reflux therapy. A split-up of
exacerbations by its cause, and investigation of cause-specific treatment effects,
might lead to a more efficient treatment of COPD exacerbations.
Research on COPD exacerbations and its treatment is still a starting field;
however it is getting more and more attention in recent years. Much research
effort is needed in the next years to improve both the understanding of COPD
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